查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1417537

標靶化脂質體給藥市場報告：至2030年的趨勢、預測與競爭分析

Targeted Liposomes Drug Delivery Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 - page report | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

標靶化脂質體給藥的趨勢與預測

預計到2030年，全球標靶化脂質體給藥市場將達到 41 億美元，2024年至2030年年複合成長率為 8.6%。該市場的主要驅動力是癌症和真菌相關感染疾病等慢性疾病盛行率的上升、對體內藥物代謝和吸收過程的了解和認知的提高以及新型治療方法採用率的提高。全球標靶化脂質體給藥市場的未來前景廣闊，真菌感染疾病治療和癌症治療市場充滿機會。

標靶化脂質體給藥市場洞察

Lucintel 預測，由於癌症發生率上升，脂質體阿黴素將在預測期內達到最高成長。

由於其高癌症發病率和先進的醫療設施，北美在預測期內將繼續成為最大的市場。

常問問題

Q1.市場規模有多大？

A1.至2030年，全球標靶化脂質體給藥市場預計將達到41億美元。

Q2.市場成長預測如何？

A2.2024年至2030年，全球標靶化脂質體年成長率成長。

Q3.影響市場成長的主要促進因素有哪些？

A3.該市場的主要驅動力是包括癌症和真菌相關感染疾病在內的慢性疾病患病率的上升、對人體藥物代謝和吸收過程的了解和認知的提高以及新型治療方法採用率的提高。

Q4.市場的主要細分市場是什麼？

A4.全球標靶化脂質體給藥市場前景廣闊，真菌感染疾病治療和癌症治療市場充滿機會。

Q5.市場上主要企業有哪些？

A5.主要標靶化脂質體給藥公司如下。

  • Catalent
  • Pacira Pharmaceuticals
  • Baxter
  • Lonza
  • Evonik
  • Merck
  • Fareva
  • Vetter
  • Polymun Scientific Immunbiologische Forschung
  • Recipharm

Q6.未來最大的細分市場是什麼？

A6.Lucintel 預測，由於癌症發生率上升，脂質體阿黴素將在預測期內呈現最高成長。

Q7.未來五年預計哪個地區將成為最大的市場？

A7.由於癌症發生率高且醫療設施先進，北美在預測期內仍將是最大的市場。

Q8.可以客製化報告嗎？

A8.是的，Lucintel 提供 10%的客製化服務，無需額外付費。

目錄

第1章 執行摘要

第2章 全球標靶化脂質體給藥市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球標靶化脂質體給藥市場趨勢（2018-2023）與預測（2024-2030）
  • 依類型分類的全球標靶化脂質體藥物遞送市場
    • 脂質體阿黴素
    • 脂質體紫杉醇
    • 脂質體雙性黴素B
    • 其他
  • 全球標靶化脂質體藥物遞送市場（依應用）
    • 真菌感染疾病的治療
    • 癌症治療
    • 其他

第4章 2018-2030年區域市場趨勢及預測分析

  • 全球標靶化脂質體給藥市場（依地區）
  • 北美標靶化脂質體給藥市場
  • 歐洲標靶化脂質體給藥市場
  • 亞太地區標靶化脂質體給藥市場
  • 其他地區標靶化脂質體給藥市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 全球標靶化脂質體給藥市場成長機會（依類型）
    • 全球標靶化脂質體給藥市場成長機會（依應用）
    • 全球標靶化脂質體給藥市場成長機會（依地區）
  • 全球標靶化脂質體給藥市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 全球標靶化脂質體給藥市場產能擴張
    • 全球標靶化脂質體給藥市場的合併、收購與合資
    • 認證和許可

第7章 主要企業概況

  • Catalent
  • Pacira Pharmaceuticals
  • Baxter
  • Lonza
  • Evonik
  • Merck
  • Fareva
  • Vetter
  • Polymun Scientific Immunbiologische Forschung
  • Recipharm
簡介目錄

Targeted Liposomes Drug Delivery Trends and Forecast

The future of the global targeted liposomes drug delivery market looks promising with opportunities in the fungal infection therapy and cancer therapy markets. The global targeted liposomes drug delivery market is expected to reach an estimated $4.1 billion by 2030 with a CAGR of 8.6% from 2024 to 2030. The major drivers for this market are rising rates of chronic illnesses including cancer and fungus-related infections, enhanced knowledge and consciousness of the body's medication metabolism and absorption processes, and rising adoption of novel therapeutic approaches.

A more than 150-page report is developed to help in your business decisions.

Targeted Liposomes Drug Delivery by Segment

The study includes a forecast for the global targeted liposomes drug delivery by type, application, and region.

Targeted Liposomes Drug Delivery Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Liposomal Doxorubicin
  • Liposomal Paclitaxel
  • Liposomal Amphotericin B
  • Others

Targeted Liposomes Drug Delivery Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Fungal Infection Therapy
  • Cancer Therapy
  • Others

Targeted Liposomes Drug Delivery Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Targeted Liposomes Drug Delivery Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies targeted liposomes drug delivery companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the targeted liposomes drug delivery companies profiled in this report include-

  • Catalent
  • Pacira Pharmaceuticals
  • Baxter
  • Lonza
  • Evonik
  • Merck
  • Fareva
  • Vetter
  • Polymun Scientific Immunbiologische Forschung
  • Recipharm

Targeted Liposomes Drug Delivery Market Insights

Lucintel forecasts that liposomal doxorubicin is expected to witness highest growth over the forecast period due to the rising incidence rate of cancers.

North America will remain the largest segment over the forecast period due to the higher cancer incidence and more sophisticated medical facilities.

Features of the Global Targeted Liposomes Drug Delivery Market

Market Size Estimates: Targeted liposomes drug delivery market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Targeted liposomes drug delivery market size by type, application, and region in terms of value ($B).

Regional Analysis: Targeted liposomes drug delivery market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the targeted liposomes drug delivery market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the targeted liposomes drug delivery market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the targeted liposomes drug delivery market size?

Answer: The global targeted liposomes drug delivery market is expected to reach an estimated $4.1 billion by 2030.

Q2. What is the growth forecast for targeted liposomes drug delivery market?

Answer: The global targeted liposomes drug delivery market is expected to grow with a CAGR of 8.6% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the targeted liposomes drug delivery market?

Answer: The major drivers for this market are rising rates of chronic illnesses including cancer and fungus-related infections, enhanced knowledge and consciousness of the body's medication metabolism and absorption processes, and rising adoption of novel therapeutic approaches.

Q4. What are the major segments for targeted liposomes drug delivery market?

Answer: The future of the global targeted liposomes drug delivery market looks promising with opportunities in the fungal infection therapy and cancer therapy markets.

Q5. Who are the key targeted liposomes drug delivery market companies?

Answer: Some of the key targeted liposomes drug delivery companies are as follows.

  • Catalent
  • Pacira Pharmaceuticals
  • Baxter
  • Lonza
  • Evonik
  • Merck
  • Fareva
  • Vetter
  • Polymun Scientific Immunbiologische Forschung
  • Recipharm

Q6. Which targeted liposomes drug delivery market segment will be the largest in future?

Answer: Lucintel forecasts that liposomal doxorubicin is expected to witness highest growth over the forecast period due to the rising incidence rate of cancers.

Q7. In targeted liposomes drug delivery market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest segment over the forecast period due to the higher cancer incidence and more sophisticated medical facilities.

Q8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the targeted liposomes drug delivery market by type (liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, and others), application (fungal infection therapy , cancer therapy, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Targeted Liposomes Drug Delivery Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Targeted Liposomes Drug Delivery Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Targeted Liposomes Drug Delivery Market by Type
    • 3.3.1: Liposomal Doxorubicin
    • 3.3.2: Liposomal Paclitaxel
    • 3.3.3: Liposomal Amphotericin B
    • 3.3.4: others
  • 3.4: Global Targeted Liposomes Drug Delivery Market by Application
    • 3.4.1: Fungal Infection Therapy
    • 3.4.2: Cancer Therapy
    • 3.4.3: others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Targeted Liposomes Drug Delivery Market by Region
  • 4.2: North American Targeted Liposomes Drug Delivery Market
    • 4.2.2: North American Targeted Liposomes Drug Delivery Market by Application: Fungal Infection Therapy , Cancer Therapy, and others
  • 4.3: European Targeted Liposomes Drug Delivery Market
    • 4.3.1: European Targeted Liposomes Drug Delivery Market by Type: Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B , and others
    • 4.3.2: European Targeted Liposomes Drug Delivery Market by Application: Fungal Infection Therapy , Cancer Therapy, and others
  • 4.4: APAC Targeted Liposomes Drug Delivery Market
    • 4.4.1: APAC Targeted Liposomes Drug Delivery Market by Type: Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B , and others
    • 4.4.2: APAC Targeted Liposomes Drug Delivery Market by Application: Fungal Infection Therapy , Cancer Therapy, and others
  • 4.5: ROW Targeted Liposomes Drug Delivery Market
    • 4.5.1: ROW Targeted Liposomes Drug Delivery Market by Type: Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B , and others
    • 4.5.2: ROW Targeted Liposomes Drug Delivery Market by Application: Fungal Infection Therapy , Cancer Therapy, and others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Targeted Liposomes Drug Delivery Market by Type
    • 6.1.2: Growth Opportunities for the Global Targeted Liposomes Drug Delivery Market by Application
    • 6.1.3: Growth Opportunities for the Global Targeted Liposomes Drug Delivery Market by Region
  • 6.2: Emerging Trends in the Global Targeted Liposomes Drug Delivery Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Targeted Liposomes Drug Delivery Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Targeted Liposomes Drug Delivery Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Catalent
  • 7.2: Pacira Pharmaceuticals
  • 7.3: Baxter
  • 7.4: Lonza
  • 7.5: Evonik
  • 7.6: Merck
  • 7.7: Fareva
  • 7.8: Vetter
  • 7.9: Polymun Scientific Immunbiologische Forschung
  • 7.10: Recipharm